Observation on the effect of tolterodine tartrate combined with Ningmitai in the treatment of overactive bladder after transurethral resection of the prostate

Abstract

Objective To investigate the efficacy and safety of tolterodine tartrate combined with Ningbitai in the treatment of overactive bladder (OAB)after transurethral resection of the prostate. Methods A retrospective study was performed on 68 cases of OAB patients who underwent transurethral resection of the prostate from January 2015 to December 2017.Patients were randomly divided into the combined treatment group and single drug treatment group, with 34 cases in each group.Patients of the single drug treatment group were treated with tolterodine tartrate, the others in the combined treatment group were given oral Ningmitai on the basis of single drug treatment group.The changes of bladder hyperactivity score (OABSS), bladder status perception scale (PPBC)and health-related quality of life scale (OAB-q)of patients in the two groups before and after treatment were compared, and the clinical treatment effect and adverse reactions of the two groups were compared. Results After treatment, OABSS score (4.2±1.1), PPBC score (2.3±0.8), OAB-q score (43.5±8.4), and the incidence of adverse reactions (5.8%)in the combined treatment group were lower than those in those in the single drug treatment group [(7.3±1.9), (4.6±1.2), (76.4±11.5)and 23.2%], the effective rate in the combined treatment group (94.1%)was higher than that in the single drug treatment group (82.4%), (P<0.05). Conclusion Tolterodine tartrate combined with Ningmitai in the treatment of OAB after transurethral resection of the prostate can significantly reduce the symptoms of patients, improve the clinical efficacy and the quality of life of patients, and has less adverse drug reactions, which is safe and reliable. Key words: Overactive bladder disease; Transurethral resection of prostate; Tolterodine tartrate; Ningmitai; Ethnic medicine